Stocklytics Platform
Asset logo for symbol TBPH
Theravance Biopharma
TBPH74
$8.53arrow_drop_down0.46%-$0.04
Asset logo for symbol TBPH
TBPH74

$8.53

arrow_drop_down0.46%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Theravance Biopharma (TBPH) Stocklytics Forecast

Theravance Biopharma Inc (TBPH) is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for various therapeutic areas. With a strong pipeline of potential drug candidates, the company has attracted the attention of investors and analysts alike. While it is always challenging to predict stock prices with certainty, there are some key factors to consider when evaluating the future prospects of TBPH.
One important aspect to consider is the company's product pipeline. Theravance Biopharma has a robust portfolio of potential therapies across different indications, including respiratory diseases, gastrointestinal disorders, and immunology. The success of these drug candidates in clinical trials and the subsequent regulatory approvals can significantly impact the company's stock price. With ongoing research and development activities and collaborations with other pharmaceutical companies, TBPH has the potential for future growth.
add Theravance Biopharma  to watchlist

Keep an eye on Theravance Biopharma

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Theravance Biopharma (TBPH) stock?

Analysts have set a target price of $21.96 for Theravance Biopharma (TBPH), based on forecasts from 27 analysts. The predicted price range extends from a high of $41 to a low of $8. This represents a potential increase of up to 380.37% and a decrease of -6.27% from the current price of $8.54. These forecasts are as of 2021 Feb 24.
help

What are the analyst ratings for Theravance Biopharma (TBPH) stock?

The analyst ratings for Theravance Biopharma (TBPH) are distributed as follows: 2 analysts recommend buying, 3 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 5 analysts leans towards a neutral rating. These ratings indicate the general sentiment among the analysts covering Theravance Biopharma .
help

What is the AI price prediction for Theravance Biopharma (TBPH) stock?

At present, there is no AI or machine-learning-based price prediction available for Theravance Biopharma (TBPH) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level